Objective To investigate the mutant status of BRAF gene and analyze its relationship to
epidemiological risk factors and clinical outcomes among patients with papillary thyroid …

Background: There is conflicting literature regarding the association of the BRAF V600E
mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC) …

Mutated BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC). To
model PTC, we bred mice with adult-onset, thyrocyte-specific expression of BRAFV600E …

Objective The somatic point mutation in the BRAF gene, which results in a valine-to-
glutamate substitution at residue 600 (BRAFV600E), is an ideal hallmark of papillary thyroid …

The very recent discovery of B-RAF point mutations as the most prevalent genetic alteration
in papillary thyroid carcinoma has revolutionized the molecular knowledge of thyroid …

The RAS→ RAF→ MEK→ MAP kinase/ERK signaling pathway (MAP kinase pathway) is a
conserved protein kinase cascade that regulates cell growth, proliferation, and differentiation …

Recent studies have demonstrated that BRAFV600E mutation is a common event in
papillary thyroid carcinoma and a majority of these lesions have shown a direct relationship …

Context: BRAFV600E is considered a primary event, a negative prognostic marker, and a
site for pharmacological intervention in papillary thyroid carcinoma (PTC). We asked …

Context: Mutually exclusive mutations of RET, RAS, or BRAF are present in about 70% of
papillary thyroid carcinomas, whereas only the latter two are seen in poorly differentiated …

BACKGROUND: Although several studies undoubtedly demonstrated that BRAF mutation is
an important genetic event in the pathogenesis of papillary thyroid carcinoma (PTC), its …